Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

RxSight Q3 Adj. EPS $(0.04) Beats $(0.38) Estimate, Sales $30.300M Beat $25.278M Estimate

Author: Benzinga Newsdesk | November 05, 2025 04:19pm
RxSight (NASDAQ:RXST) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.38) by 89.45 percent. The company reported quarterly sales of $30.300 million which beat the analyst consensus estimate of $25.278 million by 19.87 percent. This is a 14.20 percent decrease over sales of $35.314 million the same period last year.

Posted In: RXST


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist